Funding
← Back to your selection

Qiming Venture Partners

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
Rounds participated in
6
Confirmed lead rounds
—
6 roles undisclosed
New companies
5
First participation on record · 1 follow-on
Funding in participating rounds
$554M
6 disclosed · full round size, not this investor’s share

By stage

Series A2
Series C+2
Series B1
Undisclosed1

By primary sector

Biotech6

By country

China5
United States1

Rounds

6 in this selection
AusperBio

Develops oligonucleotide therapeutics targeting chronic hepatitis B

$120MSeries C
Role not disclosed
Vivacta Biotechnology

Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases

$50MSeries A+
Role not disclosed
Syneron Bio

Develops intelligent platform-driven macrocyclic peptide drug discovery

$150MSeries B
Role not disclosed
Oricell Therapeutics

Develops next-generation cell therapies for oncology and immunology

$70MSeries C1
Role not disclosed